Braxia Scientific team-led guidelines into clinical uses of ketamine and esketamine published in prestigious American Journal of Psychiatry

Braxia Scientific Corp (CSE:BRAX) (OTCMKTS:BRAXF) (FRA:496) CEO Roger McIntyre saw his research into the clinical uses of ketamine and esketamine published in the prestigious American Journal of Psychiatry. 

McIntyre and Braxia’s medical director Joshua Rosenblat led a team of 26 experts to develop the International Expert Opinion and Implementation Guidance (Guidelines) for the clinical use of rapid-acting Ketamine and Esketamine for treatment-resistant depression, according to Braxia. 

The guidelines were published in the May 2021 edition under the title “Synthesizing the Evidence for Ketamine and Esketamine for Treatment-Resistant Depression.” 

READ: Braxia Scientific appoints Dr David Greenberg, the team physician for the Toronto Argonauts, to its board of directors

According to a statement from Braxia, the guidelines aim to synthesize available literature surrounding the efficacy, safety and tolerability of intravenous ketamine and esketamine in adults living with depression that is resistant to traditional means of treatment. Additionally, McIntyre and his team aimed to provide guidance for the safe and effective implementation of the psychedelic agents in a clinical setting for medical practitioners. 

Esketamine therapy received FDA approval with “breakthrough status” in 2019. Both esketamine and intravenous ketamine are the first glutamate-based treatments demonstrated to be rapidly effective in adults suffering from treatment-resistant depression. 

In a statement, McIntyre said that the group’s goal is to support practitioners and community-based clinics offering ketamine and esketamine treatment in their ability to implement guidance and recommendations to patients to ensure the “best chance” for a safe and effective outcome.

“Our experience administering ketamine, and more recently esketamine, in a large number of people affected by treatment-resistant depression since our first clinic opened in 2018, has provided us with the opportunity to inform practitioners, internationally, on the safe, evidence-based implementation of these treatments,” McIntyre said.

“We believe the integration of science with best practices in clinics, as described in our Expert Opinion and Implementation Guidance, provides a framework for the field, and improves the probability of success for patients receiving these treatments.”

Best practices for treatment-resistant depression

Braxia Scientific is a Toronto-based medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

“With the Guidelines published in the American Journal of Psychiatry, led by psychiatrists at Braxia, we will work together with practitioners and health professionals around the world to provide education, share our expertise and best practices so that patients with treatment-resistant depression will receive the highest-quality care,” medical director Joshua Rosenblat added.

Braxia currently operates multi-disciplinary community-based clinics offering rapid-onset treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Story by ProactiveInvestors